Drug Trial Radar · NCT05512598
HB0034 in Patients With Generalized Pustular Psoriasis (GPP)
Last checked: Nov 19, 2026Latest source record: Jan 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
9
Actual
Start
Nov 6, 2022
Primary completion
Nov 15, 2023
Study completion Jan 10, 2024
Sponsor
- Lead sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 23, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of HB0034 in adult patients with generalized pustular psoriasis (GPP ).
Conditions
- Generalized Pustular Psoriasis
Interventions
HB0034Drug
HB0034, a single dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of patients with drug related adverse eventsTime frame: 90 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Dermatology Hospital of Shandong First Medical University
Shandong, Shandong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.